Company intelligence / Profile preview

OxSonics Therapeutics

Oxford, England, United Kingdomoxsonics.com ↗

Ownership: Private
Employees: ~20
Development stage: Phase 1

Overview

First-in-human clinical data show that the SonoTran® system is safe and well-tolerated. The ongoing Phase I/IIa multicenter trial in metastatic colorectal cancer has begun recruitment for efficacy cohorts. Preclinical studies have demonstrated enhanced drug penetration and efficacy across several oncology drugs and tumor models.

Therapeutic areas: Oncology
Modalities: Drug delivery platform (SonoTran®)Compatible with small molecules, antibodies, antibody-drug conjugates (ADCs), bi-specifics, oncolytic viruses
Industry: Therapeutic Medical Devices

Partnerships

Multiple pharma and biotech companies partnering to use the technology with their oncology therapiesNational Institute for Health Research (NIHR) funding support for current trial

Beyond the preview

Go deeper on OxSonics Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OxSonics Therapeutics.

Explore the full profile